• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Postmarket Trial Failures Lead Some Sponsors to Withdraw Cancer Drugs from the Market

Postmarket Trial Failures Lead Some Sponsors to Withdraw Cancer Drugs from the Market

March 15, 2021

Only about half of oncology drug sponsors granted accelerated approval by the FDA complete postmarket trial requirements the agency sets, and some sponsors have withdrawn products from the market recently in the face of an ongoing FDA review of the accelerated approval program.

In a June 2018 review of all accelerated approvals granted for malignant hematology and oncology indications from the program’s inception to May 2017, the FDA found that 40 percent of indications had not finished confirmatory trials or verified clinical benefit at that point. Out of the 93 accelerated approvals, 51 (55 percent) met their postmarket requirement and verified the product’s benefit in a median of 3.4 years after the initial approval was given.

Last week, Roche withdrew the bladder cancer indication for Tecentriq (atezolizumab) after its late-stage trial failed to meet its primary endpoint of overall survival in PD-L1-high patients. The company described its withdrawal as being motivated by “an industrywide review of Accelerated Approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals.” The FDA granted Tecentriq Accelerated Approval in 2016.

In another example, at the end of December 2020, Bristol Myers Squibb withdrew its indication for Opdivo (nivolumab) for treating small-cell lung cancer (SCLC) patients whose disease has progressed after platinum-based chemotherapy and at least one other therapy. Opdivo had won accelerated approval for SCLC in 2018 based on its effect on surrogate endpoints from a phase 1/2 trial, but its later confirmatory studies didn’t meet primary endpoints of overall survival as required.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing